Just as was the case for marijuana, public support for the legalization of psychedelic substances like psilocybin is growing steadily across the U.S. According to Green Horizons, a research firm, approximately 38% of all adults in the country believe “magic mushrooms” should be legal. The same report goes on to reveal that 25% believe that psilocybin should be legal but under controlled circumstances.
Adriana Waterston, the Senior Vice President in charge of Insights and Strategy at Green Horizons, said in a press release that there are striking parallels between the push to legalize marijuana and what is being seen in regard to psilocybin.
Just like marijuana, psychedelics have been stigmatized for decades and those negative perceptions have shaped the way these substances are regulated.
However, science is starting to demonstrate that psychedelics show great promise as treatments for a variety of psychological conditions, some of which have been treatment-resistant to the existing conventional medications.
As more research about the benefits of these compounds becomes available, there is likely to be a spike in the level of public support for legalizing psychedelics. The rate at which investors, researchers and the general public are becoming interested in psychedelics shows how quickly support for legalization is likely to grow.
Debates on this matter are already heating up in some states. In the meantime, many cities and local authorities, such as Santa Cruz, Oakland and Denver have already passed laws decriminalizing psilocybin or substances containing this compound. Washington, D.C. could also legalize these products during the polls slated for November this year.
All these regulatory changes are taking place as preliminary clinical trials suggest that psychedelics can be an effective treatment for post-traumatic stress disorder, opioid addiction, obsessive compulsive disorder, eating disorders, alcoholism, anxiety and depression.
Interestingly, psilocybin is being studied as a potential treatment for weight loss. Neon Mind, a subsidiary of Yield Growth Corp., has applied for a provisional patent in the U.S. The patent application is in relation to their invention which entails using a combination of supportive therapy and psilocybin to help patients manage their weight as well as any other related health issues that they may have. The company hopes that the psychological insights gained during the psychedelic experience can help the patient to adjust their outlook in addition to getting a break from the issues that have caused their condition. Clinical trials in this regard are planned for 2022.
All these developments show that the groundwork has been laid for psychedelics to surge in popularity in the coming years, so it isn’t surprising to see that entities like Eleusis Ltd and Numinus are ramping up their R&D in this area.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.